Immunotherapy: a promising approach for glioma treatment.

Gliomas are the most prevalent primary malignant brain tumors worldwide, with glioblastoma (GBM) being the most common and aggressive type. Despite two decades of relentless pursuit in exploring novel therapeutic approaches for GBM, there is limited progress in improving patients' survival outcomes. Numerous obstacles impede the effective treatment of GBM, including the immunosuppressive tumor microenvironment (TME), the blood-brain barrier, and extensive heterogeneity. Despite these challenges, immunotherapies are emerging as a promising avenue that may offer new hope for the treatment of gliomas. There are four main types of immunotherapies for gliomas, immune checkpoint blockades, chimeric antigen receptor T-cell therapies, vaccines, and oncolytic viruses. In addition, gene therapy, bispecific antibody therapy, and combine therapy are also briefly introduced in this review. The significant role of TME in the process of immunotherapies has been emphasized in many studies. Although immunotherapy is a promising treatment for gliomas, enormous effort is required to overcome the existing barriers to its success. Owing to the rapid development and increasing attention paid to immunotherapies for gliomas, this article aims to review the recent advances in immunotherapies for gliomas.

Yasinjan F ，Xing Y ，Geng H ，Guo R ，Yang L ，Liu Z ，Wang H ... -  《Frontiers in Immunology》

A scientometric analysis of immunotherapies for gliomas: Focus on GBM.

Gliomas are the most prevalent primary malignant brain tumors worldwide, with glioblastoma (GBM) being the most common and aggressive type. The standard therapy for GBM has remained unchanged for nearly two decades, with no significant improvement in survival outcomes. Despite several barriers such as the tumor microenvironment (TME) and blood-brain barrier, immunotherapies bring new hope for the treatment of GBM. To better understand the development and progress of immunotherapies in GBM, we made this scientometric analysis of this field. A total of 3753 documents were obtained from the Web of Science Core Collection, with publication years ranging from 1999 to 2022. The Web of Science platform, CiteSpace, and VOS viewer were used to conduct the scientometric analysis. The results of scientometric analysis showed that this field has recently become a popular topic of interest. The United States had the most publications among 89 countries or regions. Keyword analysis indicated significant areas in the field of immunotherapies for GBM, especially TME, immune checkpoint blockades (ICBs), chimeric antigen receptor T (CAR-T) cells, vaccines, and oncolytic viruses (OVs). Overall, we hope that this scientometric analysis can provide insights for researchers and promote the development of this field.

Xing Y ，Yasinjan F ，Geng H ，He M ，Yang M ，Gao Y ，Zhang J ，Zhang L ，Guo B ... -  《-》

Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.

Asija S ，Chatterjee A ，Yadav S ，Chekuri G ，Karulkar A ，Jaiswal AK ，Goda JS ，Purwar R ... -  《-》

Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.

Linares CA ，Varghese A ，Ghose A ，Shinde SD ，Adeleke S ，Sanchez E ，Sheriff M ，Chargari C ，Rassy E ，Boussios S ... -  《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》

Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.

Agosti E ，Zeppieri M ，De Maria L ，Tedeschi C ，Fontanella MM ，Panciani PP ，Ius T ... -  《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》